FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367186082> ?p ?o ?g. }

• W4367186082 endingPage "459" @default.
• W4367186082 startingPage "457" @default.
• W4367186082 abstract "Platelets are the primary target of antithrombotic therapy to prevent cardiovascular events due to their essential role in atherothrombosis. In patients who have had a recent non-cardioembolic ischaemic stroke or transient ischaemic attack (TIA), aspirin (an irreversible cyclo-oxygenase inhibitor that suppresses the synthesis of thromboxane A2) and clopidogrel (a thienopyridine that blocks the adenosine diphosphate receptor P2RY12) are often used alone or in combination to block platelet aggregation for the prevention of recurrent stroke and other major cardiovascular events. However, as these drugs have modest beneficial effects and increase the risk of major haemorrhage, in particular intracranial haemorrhage, new and different combinations of antiplatelet agents are needed to improve effectiveness and safety. These issues are particularly pertinent to patients with ischaemic stroke in China, where resistance to clopidogrel from genetic mutation in CYP2C19, delayed presentation after the onset of symptoms, little access to modern reperfusion therapy, and high rates of primary intracerebral haemorrhage from unsatisfactory control of hypertension are common factors that influence the choice of antiplatelet therapy. In The Lancet Neurology, Yuesong Pan and colleagues present results of the first clinical trial to establish if indobufen, a reversible cyclo-oxygenase inhibitor with short-term effects on platelet aggregation, 1 Lee JY Sung KC Choi HI Comparison of aspirin and indobufen in healthy volunteers. Platelets. 2016; 27: 105-109 PubMed Google Scholar could offer a safer alternative to aspirin to reduce the risk of early recurrent ischaemic stroke. 2 Pan Y Meng X Yuan B et al. Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial. Lancet Neurol. 2023; (published online April 27.)https://doi.org/10.1016/S1474-4422(23)00113-8 Summary Full Text Full Text PDF Scopus (1) Google Scholar Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trialIn patients with acute moderate-to-severe ischaemic stroke, indobufen was not non-inferior to aspirin because the upper limit of the 95% CI was greater than 1·25. Furthermore, indobufen seemed to be inferior to aspirin in reducing the risk of recurrent stroke at 90 days because the lower limit of the 95% CI was greater than 1·00. Although moderate or severe bleeding did not differ between groups, these findings do not support the use of indobufen for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke. Full-Text PDF" @default.
• W4367186082 created "2023-04-28" @default.
• W4367186082 creator A5005538880 @default.
• W4367186082 creator A5083835532 @default.
• W4367186082 date "2023-06-01" @default.
• W4367186082 modified "2023-09-28" @default.
• W4367186082 title "Antiplatelets for secondary stroke prevention in China" @default.
• W4367186082 cites W2736138957 @default.
• W4367186082 cites W3039038417 @default.
• W4367186082 cites W3164908038 @default.
• W4367186082 cites W3209828359 @default.
• W4367186082 cites W4221015477 @default.
• W4367186082 cites W4240019765 @default.
• W4367186082 cites W4367187074 @default.
• W4367186082 doi "https://doi.org/10.1016/s1474-4422(23)00130-8" @default.
• W4367186082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37121238" @default.
• W4367186082 hasPublicationYear "2023" @default.
• W4367186082 type Work @default.
• W4367186082 citedByCount "0" @default.
• W4367186082 crossrefType "journal-article" @default.
• W4367186082 hasAuthorship W4367186082A5005538880 @default.
• W4367186082 hasAuthorship W4367186082A5083835532 @default.
• W4367186082 hasConcept C118552586 @default.
• W4367186082 hasConcept C126322002 @default.
• W4367186082 hasConcept C127413603 @default.
• W4367186082 hasConcept C164705383 @default.
• W4367186082 hasConcept C16568411 @default.
• W4367186082 hasConcept C2777015399 @default.
• W4367186082 hasConcept C2777628954 @default.
• W4367186082 hasConcept C2777849778 @default.
• W4367186082 hasConcept C2780645631 @default.
• W4367186082 hasConcept C2781024287 @default.
• W4367186082 hasConcept C71924100 @default.
• W4367186082 hasConcept C78519656 @default.
• W4367186082 hasConcept C89560881 @default.
• W4367186082 hasConceptScore W4367186082C118552586 @default.
• W4367186082 hasConceptScore W4367186082C126322002 @default.
• W4367186082 hasConceptScore W4367186082C127413603 @default.
• W4367186082 hasConceptScore W4367186082C164705383 @default.
• W4367186082 hasConceptScore W4367186082C16568411 @default.
• W4367186082 hasConceptScore W4367186082C2777015399 @default.
• W4367186082 hasConceptScore W4367186082C2777628954 @default.
• W4367186082 hasConceptScore W4367186082C2777849778 @default.
• W4367186082 hasConceptScore W4367186082C2780645631 @default.
• W4367186082 hasConceptScore W4367186082C2781024287 @default.
• W4367186082 hasConceptScore W4367186082C71924100 @default.
• W4367186082 hasConceptScore W4367186082C78519656 @default.
• W4367186082 hasConceptScore W4367186082C89560881 @default.
• W4367186082 hasIssue "6" @default.
• W4367186082 hasLocation W43671860821 @default.
• W4367186082 hasLocation W43671860822 @default.
• W4367186082 hasOpenAccess W4367186082 @default.
• W4367186082 hasPrimaryLocation W43671860821 @default.
• W4367186082 hasRelatedWork W1508862217 @default.
• W4367186082 hasRelatedWork W1877581810 @default.
• W4367186082 hasRelatedWork W2002950370 @default.
• W4367186082 hasRelatedWork W2031270414 @default.
• W4367186082 hasRelatedWork W2075941057 @default.
• W4367186082 hasRelatedWork W2076238851 @default.
• W4367186082 hasRelatedWork W2171282819 @default.
• W4367186082 hasRelatedWork W2368367966 @default.
• W4367186082 hasRelatedWork W2753217352 @default.
• W4367186082 hasRelatedWork W2926542596 @default.
• W4367186082 hasVolume "22" @default.
• W4367186082 isParatext "false" @default.
• W4367186082 isRetracted "false" @default.
• W4367186082 workType "article" @default.